• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Water Street invests in generic injectable drug services company Custopharm

Water Street invests in generic injectable drug services company Custopharm

February 4, 2015
CenterWatch Staff

Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry headquartered in Chicago, has invested in Custopharm, a generic injectable drug services company. Water Street's team has committed equity to both acquire and expand the Carlsbad, Calif.-based company. The healthcare firm has recruited William Larkins, Ph.D., former vice president and general manager of Bedford Laboratories, as CEO of Custopharm.

"Water Street's partnership with us is much greater than a financial one," said Dave McCleary, co-founder and president, Custopharm. "Over the past year, its team has worked with us to develop a strategic plan and engage an experienced leader who will help us build Custopharm into a premier provider of generic injectable drug services."

Custopharm specializes in generic injectable product development and regulatory consulting services. Its team of scientists has completed formulation and methods work on a range of generic injectable products. The company has drafted and filed hundreds of abbreviated new drug applications (ANDAs) on behalf of its customers. Founded in 2005, Custopharm has worked with more than 100 organizations across the pharmaceutical industry.

"Generic injectable products are a multi-billion dollar industry growing at a double-digit annual rate," said Alan Heller, operating partner, Water Street. "Custopharm excels at sourcing materials and completing formulations to develop high-quality generic injectable products. We will expand the company's development capabilities and regulatory consulting services to meet the increasing demand for generic injectable products as more branded drugs come off patent."

Heller, who has more than 35 years of leadership experience in life sciences, will become chairman of Custopharm. Previously, he was president and CEO of American Pharmaceutical Partners (APPI). Dan Robins, Ph.D., and George Zorich also will join the board of directors.

Custopharm is Water Street's sixth investment in the pharmaceutical sector in the past six years. In 2013, Water Street partnered with a pharmaceutical company to create the drug development company Celerity Pharmaceuticals. It also invested in Temptime, which specializes in time-temperature indicators for medical products. Last year, the healthcare firm merged BioClinica, and CCBR-SYNARC to create a global provider of specialty outsourced clinical trial services.

Water Street also owned AAIPharma Services, now part of Cambridge Major Laboratories and OraPharma, which was acquired by Valeant Pharmaceuticals International in 2012.

Water Street is continuing to seek new opportunities to partner with middle-market companies interested in achieving next-level growth and corporations considering divesting non-core healthcare businesses. The firm targets investments ranging from $50 to $500 million in four healthcare sectors: specialty distribution, medical and diagnostic products, healthcare services and pharmaceutical products and services.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing